Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Debt-to-Equity?

Sichuan Kelun-Biotech Biopharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$59.5 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$6.0 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$2,548.0 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-Equity or its related term are showing as below:

HKSE:06990' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.93 Med: -0.9 Max: 0.03
Current: 0.03

During the past 3 years, the highest Debt-to-Equity Ratio of Sichuan Kelun-Biotech Biopharmaceutical Co was 0.03. The lowest was -0.93. And the median was -0.90.

HKSE:06990's Debt-to-Equity is ranked better than
82.16% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:06990: 0.03

Sichuan Kelun-Biotech Biopharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Debt-to-Equity Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

-0.90

-0.93

0.03

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
	Sep21	Dec21	Jun22	Sep22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			N/A	-1.02	-0.93	-0.16	0.03

Competitive Comparison of Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-Equity

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-Equity falls into.

Sichuan Kelun-Biotech Biopharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sichuan Kelun-Biotech Biopharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(59.508	+	6.03)	/	2547.955
	=	0.03

Sichuan Kelun-Biotech Biopharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(59.508	+	6.03)	/	2547.955
	=	0.03

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sichuan Kelun-Biotech Biopharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN

Website

http://www.kelun-biotech.com

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines